Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimer's Disease
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disorder with distinct neuropathological features. Extracellular plaques, consisting of aggregated amyloid peptides of 39-43 amino acids are one of the most prominent pathological hallmarks of this disease. Although the exact neurochemical effector mechanism of Aβ aggregation is not yet elucidated, age-associated disturbances of metal ion metabolism have been proposed to promote the formation of aggregates from soluble Aβ. Oxidative stress is postulated to be a downstream effect of Aβ-metal ion interactions. Therefore, the modulation of brain metal metabolism and attenuation of oxidative stress by antioxidant molecules are proposed as a potential therapeutic intervention in AD.
Here, we summarize the recent literature focused on APP/Aβ-metal ion interactions and the use of antioxidant metal chelators as potential therapy against AD.
Here, we summarize the recent literature focused on APP/Aβ-metal ion interactions and the use of antioxidant metal chelators as potential therapy against AD.
Keywords: Alzheimer’s disease; Amyloid beta; oxidative stress and ion chelators
Document Type: Research Article
Affiliations: Institute of Physiological Chemistry & Pathobiochemistry, Johannes Gutenberg University of Mainz, Medical School, Duesbergweg 6, D-55099 Mainz, Germany.
Publication date: 01 February 2006
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content